Pharmacotherapy for reducing saliva and droplet production in airborne procedures may help to decrease the COVID-19...

Area of Science:

• Medical Sciences
• Infectious Diseases
• Public Health

Background:

• The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic necessitates global health system preparedness.
• Preventing virus transmission during aerosol-generating medical and dental procedures is a key strategy against Coronavirus disease 2019 (COVID-19).
• Current primary recommendations focus on personal protective equipment (PPE) and sanitization practices.

Purpose of the Study:

• To explore potential pharmacotherapeutic interventions for controlling SARS-CoV-2 transmission.
• To hypothesize the role of reducing oral-respiratory secretions in mitigating COVID-19 spread.
• To investigate novel strategies beyond standard PPE for infection control.

Main Methods:

• Review of existing literature on pharmacotherapies affecting respiratory secretions.
• Hypothetical modeling of drug effects on saliva and droplet production.
• Analysis of potential benefits in aerosol-generating procedures.

Main Results:

• No specific approved interventions currently exist for preventing SARS-CoV-2 transmission via reduced secretions.
• Pharmacotherapies that decrease oral-respiratory secretions are proposed as a potential adjunct strategy.
• The hypothesis suggests a possible role in controlling virus spread during specific medical procedures.

Conclusions:

• Further research is needed to validate the efficacy of pharmacotherapies in reducing SARS-CoV-2 transmission.
• Reducing saliva and droplet production may offer a supplementary approach to infection control.
• Exploring drug solutions is a necessary step given the ongoing global health challenge.